Navigation Links
Gerresheimer Discontinues Marginal Operations
Date:6/18/2008

DUSSELDORF, Germany, June 18 /PRNewswire-FirstCall/ --

- Sale of Consumer Healthcare Business

- Concentration on Core Business of Pharmaceutics and Life Science

Gerresheimer AG, the leading manufacturer of glass and plastic products for the pharma & life science industry, is selling its consumer healthcare business. As previously announced, the Dusseldorf company is thereby discontinuing operations which are not part of the core business of pharmaceutics and life science.

"The consumer healthcare business did not fit in with our strategy of focussing on the fields of pharmaceutics and life science. In addition, because of the lack of synergies with the core business, our return requirements for the consumer healthcare business were not fulfilled," says Gerresheimer CEO Dr. Axel Herberg.

The consumer healthcare business, which comprises the production of toothbrushes and other interdental articles and most recently achieved annual sales of EUR24m, was part of the Wilden Group, which was acquired in January 2007. The purchaser is the Krallmann Group. Through the acquisition, Krallmann intends to expand its own plastic processing division and to continue the business under the traditional "Interbros" trademark. The transaction takes place with effect on 1 June 2008. The contractual parties have agreed to keep further details confidential.

Early this year, Gerresheimer already discontinued the marginal business of aluminium packaging with sales of EUR3.3m.

About Gerresheimer

Gerresheimer employs more than 10,800 people in 41 locations in Europe, America and Asia. In the financial year 2007, worldwide sales totalled EUR957.7m. The product portfolio ranges from pharma-ceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.

Contact Press Contact Investor Relations

Burkhard Lingenberg Anke Linnartz

Director Corporate PR & Marketing Director Corporate Investor Relations

Telephone +49-211-6181-250 Telephone +49-211-6181-314

Telefax +49-211-6181-241 Telefax +49-211-6181-121

E-mail E-mail

b.lingenberg@gerresheimer.com a.linnartz@gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Moodys Raises Rating for Gerresheimer
2. Gerresheimer: Record Year in 2007 and Positive Outlook for 2008
3. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
4. Yves Lionel Assant is New Chairman of Gerresheimers Supervisory Board
5. 3M Discontinues Collaboration with Gen-Probe to Develop Molecular Tests for Healthcare-Associated Infections
6. Faith Haines Kolb Joins PROMETRIKA as Senior Director of Clinical Operations and Data Management
7. Alexandria Real Estate Equities, Inc. Features Green Buildings and Sustainable Operations Initiatives and Tour at 2008 BIO
8. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
9. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
10. Medimetriks Pharmaceuticals, Inc. Begins Operations
11. Kendle Appoints Patricia Williams Vice President, Commercial Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
(Date:2/4/2016)... February 4, 2016 Strasbourg, France ... Inc. --> Strasbourg, France , to ... PharmaVentures is pleased to announce that it acted as ... manufacturing unit in Strasbourg, France , to ... --> --> Transgene (Euronext: TNG), a ...
(Date:2/3/2016)...  With the growing need for better therapeutics, ... therapies such as monoclonal antibodies, recombinant protein therapeutics ... indications are in high demand. Conventionally expression systems ... production of these therapeutics. However, due to issues ... novel approaches and novel expression systems are currently ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... new office dedicated to the North American healthcare market. , Aerocom Healthcare, LLC ... facilities. The company will provide new pneumatic tube systems or expand existing ...
Breaking Biology Technology:
(Date:1/20/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce the attainment of record-setting corporate ... of the company,s laser focus on (and growing international ... comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... growth achievements in 2015 include: , Record ...
(Date:1/18/2016)... 2016  Extenua Inc., a pioneering developer of ... and access of ubiquitous on-premise and cloud storage, today ... Cyber.  ... C4ISR and Cyber initiatives in support of National ... technology solutions," said Steve Visconti , Extenua ...
(Date:1/13/2016)... , January 13, 2016 ... published a new market report titled - Biometric Sensors Market ... Forecast, 2015 - 2023. According to the report, the global biometric ... is anticipated to reach US$1,625.8 mn by 2023, expanding ... In terms of volume, the biometric sensors market is ...
Breaking Biology News(10 mins):